Revolution Medicines shared Phase 1 data showing zoldonrasib’s acceptable safety profile in KRAS G12D mutant solid tumors at AACR 2025.
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Where Today's News Shapes Tomorrow